virnext
VirNext is a Lyon-based B2B contract research organization and academic spin-off specializing in respiratory virology, providing virus production, preclinical evaluation models, and virology services in BSL-2/BSL-3 facilities to pharmaceutical companies, biotech firms, and academic institutions.
- Company typePrivate
- Founded2012
- HeadquartersLyon, France
- Headcount1–10
- GTM typeB2B
- OfferingServices
What virnext does
VirNext is a contract research organization (CRO) and technology research platform based in Lyon, France, operating as a spin-off of Ezus Lyon 1 (a subsidiary of Université Claude Bernard Lyon 1) within the VirPath academic laboratory. Founded around 2012, the company specializes in respiratory virology and provides a continuum of preclinical research services to pharmaceutical companies, biotechnology firms, and academic institutions. Its core operations include virus library curation, virus production across multiple cell-based and egg-based systems, virology services in BSL-2 and BSL-3 facilities, and preclinical evaluation using in vitro cell line models, 3D reconstituted human airway epithelium (MucilAir/Smallair via Epithelix), and in vivo animal models including NHPs (via partner Cynbiose). The platform has been validated by regulatory-level outcomes, notably contributing to EMA approval of HIPRA's BIMERVAX COVID-19 vaccine in April 2023.
VirNext generates revenue through two primary streams: fee-for-service contract research for vaccine and antiviral candidate evaluation, and technology licensing of its proprietary IP portfolio — most notably the METAVAC live-attenuated vaccine platform (licensed exclusively to spin-off Vaxxel) and diltiazem-based host-directed antiviral combinations (licensed to Signia Therapeutics). Pricing is project-based and quote-driven, with multi-year contracts typical. The customer base is horizontally segmented across pharmaceutical companies (primary), biotechnology firms (primary), and academic consortia (secondary), with the firm embedded in a network of collaborative research structures including RESPIVIR (France-Canada), ViroCrib, and the Cynbiome alliance.
The go-to-market model relies on scientific publications, conference participation (BioFIT, LIVE2024), and consortium-based partnership formation rather than traditional sales channels. The company operates with a 10-person multidisciplinary team led by Director Manuel Rosa-Calatrava (INSERM Director of Research) and has contributed to the creation of multiple spin-offs (Vaxxel, VirexpR, Signia Therapeutics, Nexomis, AIS Biotech), establishing an ecosystem-based commercialization model where new ventures are spun out independently rather than held as subsidiaries.
virnext firmographics
Firmographics- Name
- virnext
- Legal name
- Ezus Lyon 1
- Website
- https://virnext.fr
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- VirNext is a Lyon-based B2B contract research organization and academic spin-off specializing in respiratory virology, providing virus production, preclinical evaluation models, and virology services in BSL-2/BSL-3 facilities to pharmaceutical companies, biotech firms, and academic institutions.
- Ownership category
- akta.pro rank
virnext industry classification
Industry- Product category
- Preclinical Research Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Testing Laboratories (8734)
- akta.pro primary industry
- Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)
- akta.pro secondary industry
- Zoonotic & One Health Public Health Laboratory Networks (HLAJAIAI)
Keywords
Where virnext is headquartered
LocationHeadquarters
- HQ city
- Lyon
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
virnext business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Research Services: VirNext provides fee-for-service research services including virus production, preclinical evaluation, and virology testing to pharmaceutical companies, biotech firms, and academic institutions. Revenue is generated through project-based contracts for evaluation of prophylactic and therapeutic candidates.
- Technology Licensing: Licensing of proprietary technologies including METAVAC vaccine platform to spin-offs like Vaxxel. Revenue generated through exclusive worldwide licenses of patented technologies.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom contract research services - pricing based on project scope |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
virnext product offering
Product offeringCore offering
VirNext is a technology research platform and contract research organization specializing in respiratory viruses. It provides fee-for-service virus production, virology testing, and preclinical evaluation of vaccine and antiviral candidates through in vitro cell line models, 3D reconstituted human airway epithelium (HAE) models, and in vivo animal models (mouse, ferret, hamster, non-human primate), all operated from integrated BSL-2 and BSL-3 facilities in Lyon, France.
Product overview
VirNext is a technology research platform providing a comprehensive portfolio of virus-related research services and products for the pharmaceutical and biotechnology industries. The core offering consists of four interconnected service lines: (1) Virus Library – an extensive collection of respiratory virus strains; (2) Virus Production – manufacturing of high-quality viruses and vaccine antigens using cell-based and egg-based systems; (3) Virology Services – comprehensive testing services in BSL-2/BSL-3 facilities including viral detection, vaccine response assays, compound evaluation, and quality control; and (4) Preclinical Models – in vitro models (cell lines, human airway epithelium) and in vivo models (mouse, ferret, hamster, NHP) for evaluating prophylactic and therapeutic candidates. These products form an integrated continuum enabling customers to screen compounds, produce viruses, and evaluate candidates across predictive preclinical models from early discovery through preclinical development.
Differentiator
Problem solved
Functional benefit
Brands
- SURVIR: Automated platform for rapid characterization and quantification of emerging and re-emerging respiratory pathogens based on multiplex analysis.
- METAVAC
Products and services
- Virus Library An extensive respiratory virus collection including wild-type reference and recent clinical strains, recombinant reporter viruses, and strains covering influenza A/H1N1, A/H3N2, B/Yamagata, B/Victoria, SARS-CoV-2 variants, HMPV, RSV, coronavirus, parainfluenza, adenovirus, enterovirus, and rhinovirus, supplied to pharmaceutical and biotech research teams.
- Virus Production Production of high-quality viruses and viral vaccine antigens using adherent cell cultures (A549, A549-ACE2, Hep-2, MDCK, Vero E6, LLC-MK2, HEK 293T, MRC-5), human airway epithelial cell cultures, and embryonated hen eggs at scales ranging from flasks to bioreactors (500 mL to 2 L), delivering viral supernatant, concentrated virus, purified virus, inactivated virus, split virus, and antigens.
- Virology Services Comprehensive virology services performed in BSL-2 and BSL-3 facilities, including viral detection/quantification/characterization, vaccine response assays, infection and compound evaluation, quality control, epithelial fitness assessment, potency and antiviral testing, and drug combination studies, delivered to pharmaceutical and biotech clients.
- Preclinical Models Integrated in vitro and in vivo preclinical models for evaluation of prophylactic and therapeutic candidates against respiratory viruses, combining cell line infection models, reconstituted human airway epithelium (HAE) models, and animal models (mouse, ferret, hamster, non-human primate) for translational research.
Quantifiable outcome
- Supported HIPRA BIMERVAX vaccine approval by EMA (April 2023) through preclinical studies demonstrating efficacy against SARS-CoV-2 variants
- +2 more outcomes
Companies that use virnext
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
virnext technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
virnext partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered flagship, core and minor.
- RESPIVIR International Research Laboratory (France-Canada)flagshipInternational Associated Laboratory between Université Claude Bernard Lyon 1 (France) and Université Laval/CHU de Québec (Canada). Formalized in October 2022 with INSERM joint lab label in 2024. Focuses on origin, treatment, and prevention of respiratory viral infections. Led by Manuel Rosa-Calatrava and Guy Boivin with 15+ years of collaboration history.
- ViroCrib ConsortiumflagshipCNRS-initiated national screening infrastructure for antiviral molecules across complementary preclinical models. VirNext contributes viral library, combinatorial screening expertise, and continuum of predictive in vitro and in vivo infection models.
- CynbiosecorePublic-private partnership since 2017 for evaluation of drugs, vaccines, and antibody candidates against respiratory viruses. Combines VirNext's in vitro/in vivo models with Cynbiose's NHP expertise for complete preclinical service packages.
- EpithelixcorePartnership for in vitro SARS-CoV-2 and respiratory virus infection models based on reconstituted human respiratory tissues at air-liquid interface (MucilAir, Smallair). Epithelix provides 3D reconstituted human lung tissue; VirNext performs infections in BSL-3/BSL-2 facilities.
- Cynbiome AlliancecoreExcellence preclinical research network dedicated to microbiome and infectious diseases. VirNext provides expertise in respiratory viruses and preclinical infection models. Led by Cynbiose with support from French government, BpiFrance, and Région Auvergne-Rhône-Alpes.
- VaxxelcoreSpin-off from RESPIVIR and VirNext developing METAVAC live-attenuated intranasal vaccines against RSV and HMPV. Exclusive worldwide license for METAVAC platform. Founded 2019 in Lyon.
- Signia TherapeuticscoreSpin-off licensing diltiazem-based antiviral compositions for treatment of influenza and SARS-CoV-2. Uses VirNext's SIGNATURA platform for drug identification and repurposing as broad-spectrum host-directed inhibitors.
- VirexpRcoreSpin-off focused on indoor air quality and contamination management. Develops test benches for evaluating air treatment technologies against respiratory viruses. Founded from VirPath lab and VirNext platform expertise.
- NexomisminorSpin-off launched 2024 providing bioinformatics and NGS data exploitation services. Technological support platform based on AI, mathematics, and system administration expertise.
- AIS BiotechminorSpin-off founded 2023 developing anti-infective therapeutics based on sugar-derived biopolymers. Lead candidate GlycoFlu for influenza. Leverages VirNext's virology expertise and preclinical capabilities.
- A*STAR Infectious Diseases LabscoreInternational partnership through IMMUNOVIR program structured around immune response studies, diagnostic technology development, and anti-infective immunotherapy strategies. Supported by PHCMERLION program between UCBL1 and A*STAR.
- HIPRAcoreSpanish pharmaceutical company. VirNext performed preclinical evaluation of BIMERVAX COVID-19 vaccine candidate in NHP models, contributing to EMA approval in April 2023.
- GIMAPminorResearch unit at Jean Monnet University (Saint-Étienne) focused on mucosal immunology, inflammation, and infection. Collaboration through RESPIVIR for mucosal vaccine and immunotherapy strategies.
- VirPath LaboratoryflagshipAcademic laboratory at CIRI (INSERM U1111 - CNRS UMR 5308) specializing in virology and human respiratory pathologies. Hosts National Reference Center for Respiratory Viruses. VirNext is spin-off (EZUS Lyon) of VirPath.
- ASPIDAminorDeeptech company specialized in ultra-critical containment. Partner in SHIELD project for developing innovative controlled environment solutions for airborne infectious risk control in hospitals.
- CONIDIAminorStrategic and commercial partnership with VirexpR for assessing air treatment and respiratory protection technologies in atmospheres contaminated by infectious mixtures.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
virnext competitors and assessment
Company assessmentDirect peers
- hVIVO: UK-based CRO running human respiratory virus challenge trials and preclinical virology services for pharma and biotech. Comparable to VirNext on respiratory-virus specialization, BSL capability, and customer base of pharma/biotech developing antivirals and vaccines.
- Viroclinics Biosciences: Dutch CRO specializing in respiratory virus and influenza preclinical/clinical services including BSL-3 capabilities and antiviral/vaccine evaluation. Closest functional peer to VirNext in Europe given overlapping respiratory-virus focus and similar contract-research service model.
- Cynbiose: French CRO specializing in non-human primate preclinical studies, VirNext's named NHP partner and member of the Cynbiome alliance. Directly comparable on BSL-3 in vivo respiratory virus evaluation and serves the same French/European biotech-pharma customer segment.
- NeoVirTech: French preclinical CRO offering antiviral and virucidal testing services with BSL-2/BSL-3 capabilities, listed on VirNext's partner page. Directly comparable specialized respiratory/antiviral CRO competing for similar French and European biotech-pharma contracts.
- Epithelix: Swiss provider of 3D reconstituted human airway epithelium models (MucilAir, Smallair) and respiratory toxicology/virology services. A named VirNext technology partner that competes and collaborates in HAE-based respiratory virus testing for pharma and cosmetics clients.
Broad incumbents
- SGS: Global testing, inspection, and certification company with significant health and nutrition/pharmaceutical services including virology and BSL-2/BSL-3 testing. A broad incumbent whose scale and geographic reach compete with VirNext for outsourced virology services.
- Charles River Laboratories: Global CRO offering end-to-end preclinical research including vaccine and antiviral safety/efficacy studies with BSL capabilities. A broad incumbent that competes with VirNext on bundled preclinical respiratory-virus programs from large pharma clients.
Emerging players
- ImQuest BioSciences: US CRO focused on anti-infective and antiviral preclinical development, including respiratory virus evaluation and BSL-3 work. Comparable emerging specialized CRO with similar antiviral and vaccine candidate evaluation service lines.
- Vaxxel: French biotech spin-off from RESPIVIR/VirNext developing METAVAC-based intranasal live-attenuated vaccines against RSV and HMPV. Comparable emerging vaccine developer leveraging VirNext's IP and platform; relevant peer as a downstream customer and proof point for VirNext's IP monetization model.
- IBT Bioservices: US-based infectious disease CRO offering in vivo and in vitro virology, immunology, and BSL-2/BSL-3 services for vaccines and antivirals. Comparable emerging specialized CRO with overlapping respiratory-virus and infectious-disease preclinical focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
virnext social profiles
Digital presencevirnext financial estimates
Financial estimateRevenue estimate
Valuation estimate
virnext leadership team
Management profileNumber of profiles
Profiles10 records
virnext funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
virnext M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about virnext
What does virnext do?
VirNext is a technology research platform and contract research organization specializing in respiratory viruses. It provides fee-for-service virus production, virology testing, and preclinical evaluation of vaccine and antiviral candidates through in vitro cell line models, 3D reconstituted human airway epithelium (HAE) models, and in vivo animal models (mouse, ferret, hamster, non-human primate), all operated from integrated BSL-2 and BSL-3 facilities in Lyon, France.
Is virnext a public or private company?
virnext is a private company. It is classified as corporate owned and is currently operating.
When was virnext founded?
virnext was founded in 2012. It employs 1 to 10 people.
Where is virnext based?
virnext is headquartered in Lyon, France, in the Europe region.
How does virnext make money?
Two revenue lines are on record. Contract Research Services are the primary driver. The others are technology Licensing.
Who are virnext's main competitors?
Direct peers on record are hVIVO, Viroclinics Biosciences, Cynbiose, NeoVirTech and Epithelix. Broad incumbents are SGS and Charles River Laboratories. Emerging players are ImQuest BioSciences, Vaxxel and IBT Bioservices.
Does virnext have an API?
No public API is recorded for virnext.
What industry is virnext in?
virnext's product category is Preclinical Research Services. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAJAIAI, Zoonotic & One Health Public Health Laboratory Networks. Its NAICS code is 621511 and its SIC code is 8734.